Some in vitro experiments focused on B‐cell proliferative diseases confirmed that lenalidomide had various immunomodulatory effects on lymphoma B cells and CD4+CD25+ Tregs and regulated their interactions. This evidence concerns the gene CD4 and lymphoma.